 PALO ALTO, Calif., July 28, 2021 PRNewswire -- Landing AITM announced today a software licensing agreement with Ligand Pharmaceuticals Incorporated NASDAQ: LGND to incorporate LandingLensTM into Ligands OmniAb and xPlorationTM antibody discovery platforms. 